Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07571148 · ClinicalTrials.gov registry record
Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users
A clinical trial, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- 6,876
- Enrollment target
NCT07571148: Active study, sponsored by Bristol-Myers Squibb.
NCT07571148 is a clinical trial that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 6,876 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07571148 is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- 6,876 participants
- Enrollment target
Study Summary
This study uses existing health records and insurance claims data to understand how adults in the United States are treated with KarXT, a medication for schizophrenia. It will describe who receives KarXT, how it is used in real-world practice, and how often healthcare services such as hospital visits are used. It will also explore information recorded by clinicians about schizophrenia symptoms
Primary Outcome
Number of inpatient admissions, emergency room visits, urgent care visits, and outpatient visits identified from claims and EHR data. Schizophrenia-related encounters are defined as those with a primary diagnosis of schizophrenia using ICD-10-CM codes.
Interventions
- DRUG KarXT (xanomeline and trospium)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,876 participants |
| Start Date | 2026-01-16 |
| Est. Completion | 2026-07-31 |
What the registry record for NCT07571148 still lists
NCT07571148 is an observational study that tracks outcomes without assigning an intervention. Its 6,876 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which KarXT (xanomeline and trospium) is the first listed.
NCT07571148 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07571148 about?
NCT07571148 is a clinical study titled "Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users". This study uses existing health records and insurance claims data to understand how adults in the United States are treated with KarXT, a medication for schizophrenia. It will describe who receives KarXT, how it is used in real-world practice, and how often healthcare services such as hospital visit...
What is the current status of trial NCT07571148?
This trial is currently active not recruiting. The enrollment target is 6,876 participants. The study started on 2026-01-16. Estimated completion is 2026-07-31.
What interventions are being tested in trial NCT07571148?
The interventions under investigation include: KarXT (xanomeline and trospium) (DRUG).
Who is sponsoring clinical trial NCT07571148?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06234384 · 6,833 participants
Foundation for Sarcoidosis Research Advanced Cures Registry (FSR-SARC Registry)
- NCT03887715 · 6,800 participants · NA
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
- NCT00260585 · 7,000 participants
Esophageal Cancer Risk Registry
- NCT04118660 · 7,000 participants
Thoracic Specimen Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI